Next, we evaluated the accuracy of ATN biomarkers to identify AD from MCI and found Aβ–PET (neuroimaging‐A: AUC 0.6839), tau‐PET (neuroimaging‐T: AUC 0.7893), and FDG–PET (neuroimaging‐N: AUC 0.8177) demonstrated a significantly higher AUC compared with other ATN classifications (Figure 1L). The gene discussed is MAPT; the disease is Alzheimer disease.